Life cycle approaches in the pharmaceutical and healthcare sector
In the last year, many pharmaceutical companies have made bold sustainability commitments, including net zero targets. This presentation gives on overview of the drivers behind the sector’s interest in LCA and carbon footprinting. It provides examples of where the environmental hotspots are typically found in pharmaceutical and healthcare products, highlights the challenges LCA practitioners face when conducting assessments in this industry, and presents a case study from one of ERM’s pharmaceutical clients.
Dr Andy Whiting, a consultant at global sustainability consultancy ERM, with ten years’ experience in LCA.
Andy joined ERM in 2014 and his project experience includes LCA, carbon footprinting products, carbon offsetting, scope 3 and avoided emissions. He has provided sustainability services to many major clients in the healthcare and pharma sector including a secondment to an ERM pharma client since 2015, giving him insight into sustainability issues and drivers in the sector. He was a contributing author to ERM’s Care Pathways: Guidance on Appraising Sustainability, developed for the Sustainable Healthcare Coalition.